To see the issue content and the abstract you do not have to login
Please login to download the full articles

Emailadres
Password
Lost password?      Click here!

If you do not have a subscription to Rhinology please consider to take one.
Click here to become a member of the European Rhinologic Society and a subscriber to the journal `RHINOLOGY`, beginning 2020. Subscription including membership fee: Euro 139.-

If you only want to buy this paper please click here
The price of the paper is 25 euro.


Omalizumab in patients with NSAIDs-exacerbated respiratory disease

Volume: 58 - Issue: 3

Firstpage: 226 - Lastpage: 232

U. Forster-Ruhrmann - D. Stergioudi - G. Pierchalla - J.W. Fluhr - K.-C. Bergmann - H. Olze

BACKGROUND: The association of acetylsalicylic acid (ASA) intolerance, chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, or chronic urticaria is known as NSAID-exacerbated respiratory disease (N-ERD). N-ERD patients often suffer from recurrent nasal polyps, severe asthma or also from urticaria. The aim of the present study was to retrospectively analyze the clinical efficacy of anti-IgE antibody treatment with omalizumab in patients with confirmed N-ERD.
METHODS: In the open trial with patients receiving verum patients with CRSwNP, confirmed N-ERD by oral or nasal ASA challenges, asthma or chronic urticaria were included in the study. Rhinological and pulmonary parameters were evaluated before and after 3, 6 and 9 months of therapy by rhinological questionnaires (CRS VAS-scores and RSOM-31), nasal polyp (NP)-, ACT-scores and FEV1 values. Urticaria activity was monitored clinically. N-ERD patients with aspirin desensitization were included as control group (follow-up 9 months).
RESULTS: In the omalizumab group 16 patients were included (10 female, 6 male, mean age 51 yrs). CRS symptoms, RSOM-31- and NP-score decreased significantly following omalizumab therapy compared to baseline. The ACT-score (MV 16.5 to 20.6) and FEV1values (MV 80 % to 89 %) improved significantly. No urticaria symptoms were reported after 3 months. Oral prednisolone therapy was required in one case and a repeated nasal sinus surgery in an additional case due to progression of NP. In the control group (8 female, 8 male, mean age 45 yrs) the NP-score was unchanged.
CONCLUSIONS: Omalizumab is an effective therapy option in N-ERD patients in a 9 month study period.

U. Forster-Ruhrmann - D. Stergioudi - G. Pierchalla - J.W. Fluhr - K.-C. Bergmann - H. Olze - Omalizumab in patients with NSAIDs-exacerbated respiratory disease
Rhinology 58-3: 226-232, 2020